latest news releases from the newsroom
Patient Portal Technologies, Inc.
Patient Portal Technologies to Acquire 22 Hospital Contracts, Adding $5.1 Million in Revenue
PALM BEACH GARDENS, Fla., Aug. 7, 2007 (PRIME NEWSWIRE) -- Patient Portal Technologies, Inc. (OTCBB:PPRG) announced today that the Company had agreed to acquire patient communications services contracts for 22 hospitals in the northeastern United States from Worldnet Communications Inc. of Syracuse, NY. The contracts represent approximately $5.1 million in current annual revenue and will be acquired for $1.5 million in cash and a combination of common stock and convertible Preferred Stock, with a total transaction value of $4 million. The transaction is expected to close before the end of August.
Tikvah Therapeutics, Inc.
Tikvah Therapeutics Licenses Unique Solution Formulations Useful in the Treatment of Neurodegenerative Diseases, Including Spinal Muscular Atrophy, From Navinta, LLC
ATLANTA, Aug. 7, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc. (Tikvah), a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, and Ewing, N.J.-based Navinta, LLC (Navinta) announced today that Tikvah has entered into an exclusive worldwide licensing agreement that encompasses unique solution formulations, including a proprietary formulation of sodium phenylbutyrate, and methods of use and treatments of a variety of neurodegenerative disorders including, amongst others, spinal muscular atrophy, amyotrophic lateral sclerosis and multiple sclerosis, and certain metabolic disorders.
STEC Unveils MACH8 Solid State Drive Product Family; First SSD Family Optimized for Enterprise Servers and Storage Arrays
SANTA ANA, Calif., Aug. 7, 2007 (PRIME NEWSWIRE) -- STEC (Nasdaq:STEC) today announced the MACH8(tm) product family of Solid State Drives (SSDs). Ideal as reliable, drop-in replacements for hard disk drives (HDDs), MACH8 SSDs are designed to deliver industry-leading performance and security for Enterprise storage applications at a competitive cost. MACH8 has two product variations -- a version optimized for high random read and write IOPS (MACH8-IOPS), and a base version (MACH8), making the product optimal for multiple applications in the Enterprise.
Chelsea Therapeutics Reports Second Quarter 2007 Results
CHARLOTTE, N.C., Aug. 7, 2007 (PRIME NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported financial results for the quarter and six months ended June 30, 2007, presented a quarterly update on the Company's development progress and will host a conference call this morning at 11:00 AM EDT to discuss these results.